OncLive TV

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Robb S. Friedman, MD, discusses the future of selinexor in multiple myeloma.

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.

Andrew Yee, MD, discusses treatment considerations in relapsed/refractory multiple myeloma.

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Toni K. Choueiri, MD, discusses the COVID-19 and Cancer Consortium, a multicenter effort to obtain evidence-based information on patients with cancer who have tested positive for the virus.